drugset / Trial / NCT05165485
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
RandomizedParallel-groupTriple-blindTreatment
Summary
Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
Timeline
- Start
- 2022-01-07
- Primary completion
- 2023-11-13
- Completion
- 2023-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Revefenacin | Small molecule | 175 ug | Other |
| Subject | Tiotropium | Other / unclassified | 18 ug | Inhaled |